CI
Cigna Corporation
NYSE · Healthcare · Medical - Healthcare Plans · US
$282.52
−1.31%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 282.4B | 275.0B | 247.1B | 195.3B | 180.5B |
| Cost of Revenue | 249.5B | 249.0B | 221.2B | 170.1B | 157.0B |
| Gross Profit | 32.9B | 26.0B | 26.0B | 25.2B | 23.5B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 14.0B | 14.0B | 14.6B | 14.3B | 13.0B |
| General & Admin Expense | 3.7B | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 9.2B | 2.9B | 2.0B | 2.3B | 2.0B |
| Total Operating Expenses | 23.2B | 16.9B | 16.5B | 16.6B | 15.1B |
| Cost and Expenses | 272.6B | 265.8B | 237.7B | 186.7B | 172.1B |
| Operating Income (EBIT) | 9.8B | 9.1B | 9.4B | 8.5B | 8.4B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 1.4B | 1.4B | 1.4B | 1.4B | 1.2B |
| Net Interest Income | (1.4B) | (1.4B) | (1.4B) | (1.4B) | (1.2B) |
| Other Non-Op Income/Expense | (1.3B) | (1.5B) | (4.1B) | (3.0B) | (53.0M) |
| Non-Operating Income (excl Interest) | (86.0M) | 155.0M | (275.0M) | (498.0M) | (129.0M) |
| EBT (Pre-Tax Income) | 8.5B | 7.6B | 5.3B | 5.5B | 8.4B |
| Income Tax Expense | 1.5B | 1.3B | 1.5B | 141.0M | 1.6B |
| Bottom Line | |||||
| Net Income | 6.4B | 6.0B | 3.4B | 5.2B | 6.7B |
| Earnings from Cont. Ops | 6.9B | 6.2B | 3.8B | 5.4B | 6.8B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 6.4B | 6.0B | 3.4B | 5.2B | 6.7B |
| Per Share | |||||
| Basic EPS | $24.25 | $22.30 | $12.25 | $17.57 | $21.66 |
| Diluted EPS | $24.16 | $22.17 | $12.12 | $17.39 | $21.41 |
| Revenue Per Share | $1,069.78 | $1,033.86 | $881.65 | $657.72 | $576.62 |
| Shares | |||||
| Basic Shares Outstanding | 264.0M | 265.9M | 280.3M | 296.9M | 313.1M |
| Diluted Shares Outstanding | 264.0M | 265.9M | 283.2M | 296.9M | 313.1M |
| Profitability Metrics | |||||
| EBITDA | 11.8B | 11.6B | 11.4B | 10.8B | 10.4B |
| D&A | 1.9B | 2.6B | 1.8B | 1.8B | 1.9B |
| EBIT | 9.8B | 9.0B | 9.7B | 9.0B | 8.6B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026